$ENTX
Entera Bio Ltd

2023 Q4 Form 10-Q Financial Statement

#000117891323003665 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit Margin
Selling, General & Admin $973.0K $1.030M
YoY Change -44.11% -29.45%
% of Gross Profit
Research & Development $1.000M $1.370M
YoY Change -25.98% -3.04%
% of Gross Profit
Depreciation & Amortization $13.00K $10.00K
YoY Change -18.75% -37.5%
% of Gross Profit
Operating Expenses $1.963M $2.386M
YoY Change -36.14% -16.78%
Operating Profit -$1.963M -$2.386M
YoY Change -36.02% -16.72%
Interest Expense -$32.00K $40.00K
YoY Change -600.0%
% of Operating Profit
Other Income/Expense, Net $36.00K
YoY Change -550.0%
Pretax Income -$1.995M -$2.350M
YoY Change -35.25% -18.2%
Income Tax $0.00 $29.00K
% Of Pretax Income
Net Earnings -$1.995M -$2.379M
YoY Change -34.27% -22.43%
Net Earnings / Revenue
Basic Earnings Per Share $0.08
Diluted Earnings Per Share -$0.07 $0.08
COMMON SHARES
Basic Shares Outstanding 28.81M shares 28.81M shares
Diluted Shares Outstanding 28.81M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.02M $7.590M
YoY Change -10.48% -47.01%
Cash & Equivalents $11.02M $7.585M
Short-Term Investments
Other Short-Term Assets $238.0K $263.0K
YoY Change -19.05% -58.52%
Inventory
Prepaid Expenses $34.00K $168.0K
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $11.26M $8.016M
YoY Change -12.39% -47.23%
LONG-TERM ASSETS
Property, Plant & Equipment $488.0K $108.0K
YoY Change 251.08% -28.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $20.00K
YoY Change -59.18% -72.22%
Total Long-Term Assets $508.0K $549.0K
YoY Change 82.73% 56.86%
TOTAL ASSETS
Total Short-Term Assets $11.26M $8.016M
Total Long-Term Assets $508.0K $549.0K
Total Assets $11.77M $8.565M
YoY Change -10.38% -44.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $83.00K $564.0K
YoY Change 388.24% 36.56%
Accrued Expenses $1.008M $1.460M
YoY Change -23.87% 87.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.091M $2.027M
YoY Change -18.64% 69.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $288.0K $300.0K
YoY Change 800.0% 757.14%
Total Long-Term Liabilities $288.0K $302.0K
YoY Change 800.0% 762.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.091M $2.027M
Total Long-Term Liabilities $288.0K $302.0K
Total Liabilities $1.379M $2.329M
YoY Change 0.44% 89.66%
SHAREHOLDERS EQUITY
Retained Earnings -$104.4M -$102.4M
YoY Change 9.32% 10.69%
Common Stock $114.7M $108.6M
YoY Change 7.02% 1.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.39M $6.236M
YoY Change
Total Liabilities & Shareholders Equity $11.77M $8.565M
YoY Change -10.38% -44.88%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.995M -$2.379M
YoY Change -34.27% -22.43%
Depreciation, Depletion And Amortization $13.00K $10.00K
YoY Change -18.75% -37.5%
Cash From Operating Activities -$2.617M -$1.520M
YoY Change 30.13% -47.02%
INVESTING ACTIVITIES
Capital Expenditures $5.000K $0.00
YoY Change 66.67% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$5.000K $0.00
YoY Change 66.67% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.031M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.617M -1.520M
Cash From Investing Activities -5.000K 0.000
Cash From Financing Activities 6.031M 0.000
Net Change In Cash 3.409M -1.520M
YoY Change -269.27% -48.05%
FREE CASH FLOW
Cash From Operating Activities -$2.617M -$1.520M
Capital Expenditures $5.000K $0.00
Free Cash Flow -$2.622M -$1.520M
YoY Change 30.19% -46.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7676000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14390000 usd
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
431000 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
120000 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Revenues
Revenues
8000 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
93000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Gross Profit
GrossProfit
27000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6865000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9853000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2350000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2873000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
183000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
194000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6894000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10036000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.35
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28812122 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28812122 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28807470 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28807470 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
431000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
294000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
46000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
174000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
174000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
83000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
477000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
75000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
402000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Security12b Title
Security12bTitle
Ordinary Shares
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
294000 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
6000 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
2000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3510000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4497000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3457000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5512000 usd
us-gaap Other Nonrecurring Income
OtherNonrecurringIncome
39000 usd
us-gaap Other Nonrecurring Income
OtherNonrecurringIncome
33000 usd
CY2023Q3 us-gaap Other Nonrecurring Income
OtherNonrecurringIncome
12000 usd
us-gaap Operating Expenses
OperatingExpenses
6928000 usd
us-gaap Operating Expenses
OperatingExpenses
9976000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6928000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9949000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
63000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
96000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
36000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
5000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2379000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
383000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6236000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22565000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
17269000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3067000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
110000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
14312000 usd
entx Funds In Respect Of Employee Rights Upon Retirement
FundsInRespectOfEmployeeRightsUponRetirement
0 usd
entx Funds In Respect Of Employee Rights Upon Retirement
FundsInRespectOfEmployeeRightsUponRetirement
55000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12376000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24964000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
165000 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6999180 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6068670 shares

Files In Submission

Name View Source Status
entx-20230930_cal.xml Edgar Link unprocessable
entx-20230930_def.xml Edgar Link unprocessable
0001178913-23-003665-index-headers.html Edgar Link pending
0001178913-23-003665-index.html Edgar Link pending
0001178913-23-003665.txt Edgar Link pending
0001178913-23-003665-xbrl.zip Edgar Link pending
entx-20230930.xsd Edgar Link pending
exhibit_31-1.htm Edgar Link pending
exhibit_31-2.htm Edgar Link pending
exhibit_32-1.htm Edgar Link pending
exhibit_32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
entx-20230930_lab.xml Edgar Link unprocessable
entx-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zk2330397.htm Edgar Link pending
zk2330397_htm.xml Edgar Link completed